Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Cash & Current Investments (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Cash & Current Investments data on record, last reported at $20.4 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments rose 139.75% year-over-year to $20.4 million; the TTM value through Dec 2025 reached $20.4 million, up 139.75%, while the annual FY2025 figure was $20.4 million, 139.75% up from the prior year.
  • Cash & Current Investments reached $20.4 million in Q4 2025 per TLSI's latest filing, down from $22.7 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $26.5 million in Q2 2025 and bottomed at $50930.0 in Q1 2022.
  • Average Cash & Current Investments over 4 years is $11.1 million, with a median of $11.3 million recorded in 2024.
  • The widest YoY moves for Cash & Current Investments: up 15750.93% in 2024, down 47.21% in 2024.
  • A 4-year view of Cash & Current Investments shows it stood at $9.4 million in 2022, then rose by 25.1% to $11.8 million in 2023, then decreased by 27.61% to $8.5 million in 2024, then soared by 139.75% to $20.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $20.4 million in Q4 2025, $22.7 million in Q3 2025, and $26.5 million in Q2 2025.